Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK50042 in Subjects With Idiopathic Pulmonary Fibrosis

NCT07728721 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07728721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07728721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK50042 in Subjects With Idiopathic Pulmonary Fibrosis
Lead sponsor
Haisco Pharmaceutical Group Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 25, 2026
Completion date
July 25, 2028
Enrollment
175 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis (ipf)